NCT05248867
Brief summary
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. AGN-151586 is an investigational product being developed for the treatment of GL. The purpose of this study was to evaluate the safety and efficacy of AGN-151586 for the treatment of GL in participants with moderate to severe GL. This was a 12-week study in which eligible subjects were enrolled into the study containing 2 treatment periods, double-blind period and open-label period. Participants were randomly assigned to receive AGN-151586 or placebo. There was 1 in a 4 chance that participants would receive placebo. Around 600 adult participants with moderate to severe GL were to be enrolled in the study in approximately 38 sites across the world. Participants received either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may have received an open-label treatment of AGN-151586 during the study. Participants attended regular visits during the study at a study site. The effect of the treatment was checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.
Interventional study
- 1
- 2
- 3
- 4
Age:
18 Years and older.
Inclusion Criteria:
- Participants must be able to accurately assess their facial lines without the use of
eyeglasses (contact lens use is acceptable).
- Participant must have moderate or severe Glabellar Lines at maximum frown as assessed
by both the investigator and participant using the Facial Wrinkle Scale (FWS) at
Screening and Baseline Day 1 visit.
Exclusion Criteria:
- Uncontrolled systemic disease.
- Presence or history of any medical condition that may place the participant at
increased risk following exposure to AGN-151586 or interfere with the study
evaluation, including:
- Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral
sclerosis, or any other significant disease that might interfere with
neuromuscular function
- History of facial nerve palsy
- Infection or dermatological condition at the treatment injection sites
- Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick
sebaceous skin, excessively photodamaged skin, or the inability to substantially
lessen facial lines even by physically spreading them apart
- Any eyebrow or eyelid ptosis at screening or Baseline Day 1 visit as determined
by the investigator
- History of known immunization to any botulinum neurotoxin serotype.
- Participants who have reported use of any botulinum neurotoxin of any serotype
(including any investigational botulinum neurotoxin product) for aesthetic treatment
within the last 6 months prior to Baseline (Day 1 of treatment) and for therapeutic
treatment within the last 12 months prior to study drug administration.
- Tattoos, jewelry, or clothing which obscure the glabellar area and cannot be removed.
- Anticipated need for surgery or overnight hospitalization during the study.
- History of surgical procedures on forehead and/or periorbital areas or affecting these
areas including any lifting procedure (e.g., rhinoplasty, facial lift, suture lift,
thread lift, brow lift, eyelid and/or eyebrow surgery).
- History of periorbital, mid-facial, or upper-facial treatment with semi-permanent or
permanent soft tissue fillers (e.g., poly-L-lactic acid, polyalkylimide,
polymethylmethacrylate, polytetrafluoroethylene, and silicone), synthetic implantation
and/or autologous fat transplantation.
- Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Female participant who is pregnant or breastfeeding, and is considering becoming
pregnant or donating eggs during the study or for approximately 30 days after the last
dose of study drug or until the end of study, whichever is longer.
- Participant who has been treated with any investigational drug within 30 days or 5
half-lives of the drug (whichever is longer) prior to the first dose of study drug or
is currently enrolled in another clinical study or was previously enrolled in this
study.
- Anticipated need for treatment with botulinum neurotoxin of any serotype for any
reason during the study (other than study drug).
